It is thus unlikely that the total CRM content of a vaccine, or of a series of vaccinations, is the sole source of interference in Hib antibody responses and other causes need to be considered.
Consistent evidence that PHiD-CV boosted Hib responses was observed. There are three different carrier PJ34 in the PHiD-CV vaccine and the effect on Hib responses has been attributed to the TT component of the vaccine [25]. It is however possible that protein D might influence Hib responses, however there is no licensed vaccine which uses protein D as the sole carrier protein so this remains theory only.
The boosting of Hib responses with MenACWY administration was surprising considering the significant suppression of Hib responses seen with MenC-CRM. The oligosaccharide in both types of MenC vaccine (MenC-CRM and MenC-TT) is adsorbed on aluminium hydroxide 0.3–0.4 mg Al3+ whereas MenACWY vaccine contains no adjuvant and this may be a factor in the differences seen between these two different vaccines.
Consistent evidence that PHiD-CV boosted Hib responses was observed. There are three different carrier PJ34 in the PHiD-CV vaccine and the effect on Hib responses has been attributed to the TT component of the vaccine [25]. It is however possible that protein D might influence Hib responses, however there is no licensed vaccine which uses protein D as the sole carrier protein so this remains theory only.
The boosting of Hib responses with MenACWY administration was surprising considering the significant suppression of Hib responses seen with MenC-CRM. The oligosaccharide in both types of MenC vaccine (MenC-CRM and MenC-TT) is adsorbed on aluminium hydroxide 0.3–0.4 mg Al3+ whereas MenACWY vaccine contains no adjuvant and this may be a factor in the differences seen between these two different vaccines.